» Articles » PMID: 22006458

Longitudinal Study of the Impact of Incident Organ Manifestations and Increased Disease Activity on Work Loss Among Persons with Systemic Lupus Erythematosus

Overview
Specialty Rheumatology
Date 2011 Oct 19
PMID 22006458
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: There is increasing evidence of the impact of systemic lupus erythematosus (SLE) on employment, but few studies have had sufficient sample size and longitudinal followup to estimate the impact of specific manifestations or of increasing disease activity on employment.

Methods: Data were derived from the University of California, San Francisco, Lupus Outcomes Study, a longitudinal cohort of 1,204 persons with SLE sampled between 2002 and 2009. Of the 1,204 persons, 484 were working at baseline and had at least 1 followup interview. We used the Kaplan-Meier method to estimate the time between onset of thrombotic, neuropsychiatric, or musculoskeletal manifestations, or of increased disease activity, and work loss. We used Cox proportional hazards regression to estimate the risk of work loss associated with the onset of specific manifestations, the number of manifestations, and increased activity, with and without adjustment for sociodemographic, employment, and SLE duration characteristics.

Results: By 4 years of followup, 57%, 34%, and 38% of those with thrombotic, musculoskeletal, and neuropsychiatric manifestations, respectively, had stopped working, as had 42% of those with increased disease activity. On a bivariable basis, the risk of work loss was significantly higher among persons ages 55-64 years and those with increased disease activity and each kind of manifestation. In multivariable analysis, older age, shorter job tenure, thrombotic and musculoskeletal manifestations, greater number of manifestations, and high levels of activity increased the risk of work loss.

Conclusion: Incident thrombosis and musculoskeletal manifestations, multiple manifestations, and increased disease activity are associated with the risk of work loss in SLE.

Citing Articles

Work participation in patients with systematic lupus erythematosus: a systematic review.

Blomjous B, Gajadin G, Voskuyl A, Falzon L, Hoving J, Bultink I Rheumatology (Oxford). 2021; 61(7):2740-2754.

PMID: 34792543 PMC: 9258549. DOI: 10.1093/rheumatology/keab855.


Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus.

Di Matteo A, Smerilli G, Cipolletta E, Salaffi F, De Angelis R, Di Carlo M Curr Rheumatol Rep. 2021; 23(9):73.

PMID: 34269905 PMC: 8285327. DOI: 10.1007/s11926-021-01040-8.


Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus.

Bjork M, Dahlstrom O, Wettero J, Sjowall C BMC Musculoskelet Disord. 2015; 16:188.

PMID: 26264937 PMC: 4531389. DOI: 10.1186/s12891-015-0621-3.


Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s.

Albrecht K, Huscher D, Richter J, Backhaus M, Bischoff S, Kotter I Lupus Sci Med. 2015; 1(1):e000059.

PMID: 25553251 PMC: 4271412. DOI: 10.1136/lupus-2014-000059.


Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Turchetti G, Yazdany J, Palla I, Yelin E, Mosca M Clin Exp Rheumatol. 2012; 30(4 Suppl 73):S116-22.

PMID: 23072767 PMC: 3714226.

References
1.
Yazdany J, Yelin E, Panopalis P, Trupin L, Julian L, Katz P . Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis Rheum. 2008; 59(1):136-43. PMC: 3759159. DOI: 10.1002/art.23238. View

2.
Cervera R, Khamashta M, Shoenfeld Y, Camps M, Jacobsen S, Kiss E . Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2008; 68(9):1428-32. DOI: 10.1136/ard.2008.093179. View

3.
Panopalis P, Julian L, Yazdany J, Gillis J, Trupin L, Hersh A . Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum. 2007; 57(8):1453-60. PMC: 2875137. DOI: 10.1002/art.23090. View

4.
Ruiz-Irastorza G, Egurbide M, Ugalde J, Aguirre C . High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004; 164(1):77-82. DOI: 10.1001/archinte.164.1.77. View

5.
Appenzeller S, Cendes F, Costallat L . Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum. 2009; 61(5):680-7. DOI: 10.1002/art.24346. View